Cigarette Smoking-Related CarcinomaNCT05825001
Evaluating the Episodic Future Thinking Intervention for Reducing Cigarette Consumption in Cigarette Smokers
A study testing Smoking Cessation Intervention and Medical Device Usage and Evaluation in people with Cigarette Smoking-Related Carcinoma, run by Roswell Park Cancer Institute at 1 site in United States.
Trial summary
This clinical trial evaluates the effectiveness of active episodic future thinking (EFT) stimuli for reducing cigarette consumption in cigarette smokers. EFT is an innovative framing method shown to significantly activate brain regions involved in future thinking, planning, and other executive functions. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cigarette Smoking-Related Carcinoma
- What is being tested?
- Smoking Cessation Intervention and Medical Device Usage and Evaluation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 104 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Sep 2024to 5 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Smoke >= 10 cigarettes daily
- >32 on the Vividness of Visual Imagery Questionnaire (VVIQ)
- No regular use of other tobacco products
- In possession of a smartphone with text messaging capabilities
- Willing to quit smoking in the next 30 days
- Low socioeconomic status
- Veteran of the US armed services
Who cannot join
- Unable or unwilling to provide verbal consent
- Unable or unwilling to provide data to the research team
- Current use of nicotine replacement therapy, bupropion, or varenicline
- Use of drugs of abuse in the past 30 days
- Living in the same household as a participant already enrolled in this study
- Unable or unwilling to use nicotine patches
Trial locations and contacts
1 site in 1 country.
United States1 site
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263
About this study
Official title: Pilot Study of Episodic Future Thinking Among Cigarette Smokers
This clinical trial evaluates the effectiveness of active episodic future thinking (EFT) stimuli for reducing cigarette consumption in cigarette smokers. EFT is an innovative framing method shown to significantly activate brain regions involved in future thinking, planning, and other executive functions. Active EFT stimuli are positive events, unrelated to smoking, that participants anticipate, look forward to, and can vividly imagine happening up to 1 year in the future. Control EFT stimuli are positive past events, unrelated to smoking, that participants can vividly remember happening in the recent past. Active EFT stimuli may help reduce cigarette consumption among cigarette smokers by exposing them to personally relevant future oriented stimuli.
Read the detailed description
PRIMARY OBJEECTIVE:
- To evaluate the efficacy of episodic future thinking (EFT) for smoking cessation.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I (ACTIVE): Participants receive the active EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.
ARM II (CONTROL): Participants receive the control EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.
- Conditions
- Cigarette Smoking-Related Carcinoma
- Being tested
- Smoking Cessation Intervention, Smoking Cessation Intervention (control), Medical Device Usage and Evaluation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Smoking Cessation InterventionBehavioural
Also called Smoking and Tobacco Use Cessation Interventions
Receive active EFT stimulus
Smoking Cessation Intervention (control)Behavioural
Also called Smoking and Tobacco Use Cessation Interventions
Receive control EFT stimulus
Medical Device Usage and EvaluationOther
Use iCOquit Smokerlyzer carbon monoxide monitor
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 (active EFT) | Experimental | Participants receive the active EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study. Receives: Behavioral: Smoking Cessation Intervention; Other: Medical Device Usage and Evaluation |
| Arm II (control EFT) | Active comparator | Participants receive the control EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study. Receives: Behavioral: Smoking Cessation Intervention (control); Other: Medical Device Usage and Evaluation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Concentration of carbon monoxide on breath
Will be measured by Micro+Basic carbon monoxide monitor
Measured: From baseline up to 30 days
Secondary outcomes (1)
Reduction in delay discounting rate
participants will be guided to imagine the situational and sensory details for each of the stimuli until the vividness scores are ≥ 4 on a scale of 1-5 (1=very low, 5=very high).
Measured: Up to 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2023
- Study start15 Sep 2024
- Primary completion1 Oct 2025
- Study completion5 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cigarette Smoking-Related CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 104 participants (actual)
Sponsor and investigators
- Lead sponsor
- Roswell Park Cancer Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Christine Sheffer, Principal investigator, Roswell Park
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05825001
- Sponsor's protocol ID
- I 2684022
- Status last verified
- Jun 2026
- First submitted
- 11 Apr 2023
- Last updated
- 22 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Study of Episodic Future Thinking Among Cigarette Smokers
- ClinicalTrials.gov ID
- NCT05825001
- Acronym / sponsor ID
- I 2684022
- Conditions
- Cigarette Smoking-Related Carcinoma
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 104 participants (actual)
- Lead sponsor
- Roswell Park Cancer InstituteUniversity, hospital or other
- Study start
- 15 Sep 2024 (actual)
- Primary completion
- 1 Oct 2025 (actual)
- Study completion
- 5 Jun 2026 (actual)
- First posted
- 24 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial evaluates the effectiveness of active episodic future thinking (EFT) stimuli for reducing cigarette consumption in cigarette smokers. EFT is an innovative framing method shown to significantly activate brain regions involved in future thinking, planning, and other executive functions. Active EFT stimuli are positive events, unrelated to smoking, that participants anticipate, look forward to, and can vividly imagine happening up to 1 year in the future. Control EFT stimuli are positive past events, unrelated to smoking, that participants can vividly remember happening in the recent past. Active EFT stimuli may help reduce cigarette consumption among cigarette smokers by exposing them to personally relevant future oriented stimuli.
Detailed description
PRIMARY OBJEECTIVE:
- To evaluate the efficacy of episodic future thinking (EFT) for smoking cessation.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I (ACTIVE): Participants receive the active EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.
ARM II (CONTROL): Participants receive the control EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm 1 (active EFT) | Experimental | Behavioral: Smoking Cessation Intervention, Other: Medical Device Usage and EvaluationParticipants receive the active EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study. |
| Arm II (control EFT) | Active comparator | Behavioral: Smoking Cessation Intervention (control), Other: Medical Device Usage and EvaluationParticipants receive the control EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Smoke >= 10 cigarettes daily
- >32 on the Vividness of Visual Imagery Questionnaire (VVIQ)
- No regular use of other tobacco products
- In possession of a smartphone with text messaging capabilities
Key exclusion criteria (6 listed)
- Unable or unwilling to provide verbal consent
- Unable or unwilling to provide data to the research team
- Current use of nicotine replacement therapy, bupropion, or varenicline
- Use of drugs of abuse in the past 30 days
- Living in the same household as a participant already enrolled in this study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Smoking Cessation InterventionAlso: Smoking and Tobacco Use Cessation InterventionsReceive active EFT stimulus | Behavioural | Arm 1 (active EFT) |
| Smoking Cessation Intervention (control)Also: Smoking and Tobacco Use Cessation InterventionsReceive control EFT stimulus | Behavioural | Arm II (control EFT) |
| Medical Device Usage and EvaluationUse iCOquit Smokerlyzer carbon monoxide monitor | Other | Arm 1 (active EFT), Arm II (control EFT) |
Primary outcome
Concentration of carbon monoxide on breath
Time frame: From baseline up to 30 days
Will be measured by Micro+Basic carbon monoxide monitor
1 secondary outcome
Reduction in delay discounting rate
Time frame: Up to 30 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Cigarette Smoking-Related Carcinoma
RecruitingEarly Phase 1
Sensory Tests of Cigarettes for Identification of Flavors in Current Daily Smoking Adults
Cigarette Smoking-Related Carcinoma
Not yet recruiting
A Smartphone Application (QuitBot) for the Improvement of Smoking Cessation Among American Indians and Alaska Natives, NAITIVE Trial
Cigarette Smoking-Related Carcinoma
RecruitingPhase 3
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Cigarette Smoking-Related Carcinoma
RecruitingPhase 4
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
Cigarette Smoking-Related Carcinoma
Recruiting
Evaluating the Effect of Nicotine on Eye Movements and Related Behaviors in Electronic Cigarette Users, NICS-EYES Trial
Cigarette Smoking-Related Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christine Sheffer principal investigator
Roswell Park
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Smoking Cessation Intervention and Medical Device Usage and Evaluation in people with Cigarette Smoking-Related Carcinoma, run by Roswell Park Cancer Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Concentration of carbon monoxide on breath (time frame: From baseline up to 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.